The fight over prescription drug prices is moving from Washington hearings into state capitals, and investors should treat that shift as more than political noise. States are advancing new restrictions on pharmacy benefit managers. The latest wave is aimed not only at transparency, but at the ownership structure that lets some of the biggest PBMs also own pharmacies.
That makes the issue a direct financial test for CVS Health, Cigna and UnitedHealth Group, whose Caremark, Express Scripts and Optum Rx businesses sit at the center of the U.S. prescription supply chain. PBMs say scale lets them negotiate discounts and hold down plan spending. State lawmakers are now asking whether that same scale gives vertically integrated companies too much power over reimbursement, pharmacy access and where prescription revenue ultimately flows.
The Associated Press reported this weekend that lawmakers in at least 26 states introduced more than 120 PBM-related bills this year, with at least a dozen states passing laws to limit compensation, require disclosure or mandate minimum pharmacist payments. A one-state dispute can be treated as litigation risk. A national pattern starts to look like a structural threat to a profit pool built on complex contracts and pharmacy networks.
Tennessee is the sharpest example. Its new law would bar PBMs from operating retail pharmacies beginning July 1, 2028, and CVS has sued in federal court to block it. AP reported that CVS says it operates 136 pharmacies in Tennessee, while Healthcare Dive has reported that Express Scripts and the PBM trade group PCMA have also sued over the law. The legal fight will test whether states can break up PBM-pharmacy ownership links, or whether federal preemption and interstate commerce arguments protect the current integrated model.
Kansas shows the less dramatic but potentially more replicable version of the pressure. Governor Laura Kelly signed Senate Bill 20 in April, describing it as a framework to regulate PBMs, increase transparency and strengthen accountability. The Kansas Insurance Department says the law takes effect July 1, 2026. AP reported that Kansas will require PBMs to pay a $10.50 dispensing fee per prescription, a provision supporters say can help keep local pharmacies viable and critics say could raise costs elsewhere in the system.
The political backdrop is favorable for more regulation. KFF polling published in March found that 59% of U.S. adults are worried about affording prescription drug costs for themselves or their families, the highest share since KFF began asking the question in 2018. It also found that 43% of adults reported not taking medicine as prescribed at some point in the past year because of cost. Those figures make PBM reform easy to frame as consumer protection, small-business protection and anti-concentration policy at once.
For investors, the key is not whether every state law survives intact. It is whether the negotiating position of the largest PBMs is being reset. The Federal Trade Commission’s 2024 interim staff report said the top three PBMs processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by U.S. pharmacies in 2023, and argued that vertical integration gives leading PBMs significant influence over access, pricing and pharmacy choice. CVS disputes that framing, saying CVS Caremark helps employers, unions and health plans expand access to affordable medications through formularies, clinical programs and negotiated discounts.
Both things can be true in the market’s eyes. PBMs may produce real savings for plan sponsors while still facing rising legal and political resistance to opaque pricing, pharmacy steering and ownership conflicts. The risk is not a sudden collapse of the PBM model. It is margin compression, compliance fragmentation and less freedom to use affiliated pharmacies as part of a broader health care platform.
CVS has especially visible exposure because the Tennessee case directly targets PBM-owned pharmacies. Cigna and UnitedHealth also have reason to watch the litigation because Express Scripts and Optum Rx are among the dominant PBMs named in the broader policy debate. If state rules spread, investors may ask how much earnings quality depends on vertical integration rather than scale alone.
The PBM crackdown is still early, uneven and headed for the courts. But drug affordability has become a household finance issue, and state legislators are beginning to attack the architecture of the industry rather than only its disclosure practices. For health care intermediaries, it turns a familiar policy fight into a test of whether their integrated model can survive when the rules are written closer to the pharmacy counter.